<DOC>
	<DOCNO>NCT00145626</DOCNO>
	<brief_summary>Recent study conventional chemotherapy infant high-risk hematologic malignancy show long-term disease-free survival low . Although blood marrow stem cell transplantation use HLA identical sibling improve outcome child , le 25 % donor source available . Another option haploidentical transplantation use partially match family member donor ( i.e . parental donor ) . Although haploidentical transplantation proven curative patient , procedure hinder significant complication , primarily regimen-related toxicity include infection graft versus host disease ( GVHD ) . Building prior institutional trial , study provide patient haploidentical graft deplete T lymphocytes use investigational device , CliniMACS selection system . One week transplant procedure , patient also receive infusion additional donor derive white blood cell call Natural Killer ( NK ) cell effort decrease risk rejection graft , disease relapse , regimen related toxicity . The primary objective study evaluate 1 year survival infant high risk hematologic malignancy receive study treatment .</brief_summary>
	<brief_title>HLA-Nonidentical Stem Cell Natural Killer Cell Transplantation Children Less Two Years Age With Hematologic Malignancies</brief_title>
	<detailed_description>Secondary objective study include follow : - To estimate incidence three transplant-related adverse outcome ( i.e. , regimen-related mortality , engraftment failure , fatal acute GVHD ) first 100 day transplantation . - To estimate incidence chronic graft-versus-host disease . - To evaluate factor affect one-year survival . - To assess kinetics lymphohematopoietic reconstitution . - To assess frequency clinical relevance minimal residual disease ( MRD ) transplantation . - To evaluate incidence risk factor long-term neurocognitive deficit organ dysfunction .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Histiocytosis</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<criteria>Must one follow diagnosis : AML remission relapse ( e.g. , FAB M7 biphenotypic leukemia ) Highrisk ALL first remission ( e.g. , poor responder prednisone , Ph+ ALL ) ALL beyond first remission Secondary leukemia Primary myelodysplasia ( include RAEB , RAEBT , CMML , JCML , JMML ) Chronic myeloid leukemia Histiocytoses ( include multisystem Langerhans ' cell histiocytosis hemophagocytic lymphohistiocytosis Inclusion criterion Donor research participant HIV negative ( date ) . Hepatitis B surface antigen negative ( date ) . Hepatitis C antibody negative ( date ) . Syphilis negative ( date ) . Donor equal great 3 6 HLA match ( date ) . Not pregnant ( negative pregnancy test ) . Not lactate . At least 18 year age . Exclusion Criteria Patients great 24 month age time transplant . HLAidentical sibling donor available . Cardiac function : shortening fraction &lt; 25 % . Pulse oximetry oxygen saturation &lt; 92 % room air . Glomerular filtration rate le 40 ml/min/1.73 m2 ( may use Technetium99 result GFR ) . Direct bilirubin &gt; 3 mg/dl . SGPT &gt; 500 U/L . Patients previous allergy mouse protein . Patients previous allergy rabbit serum product . Patients Down 's syndrome</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>24 Months</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Stem cell transplantation</keyword>
	<keyword>Stem cell transplant</keyword>
	<keyword>Haploidentical transplant</keyword>
</DOC>